Semaglutide and Kidney Disease: What the FLOW Trial Actually Showed

Semaglutide entered public awareness as a glucose-lowering and weight-loss drug. The FLOW trial is the study that pushed it into a third arena entirely: kidney protection. For anyone keeping a research log on GLP-1 receptor agonists, FLOW is a landmark data point because it moved semaglutide from "treats the metabolic numbers" to "changes hard clinical outcomes" in a high-risk population.

This is a summary of published evidence, not clinical guidance. See our semaglutide reference page for background on the molecule, and FDA status for how its regulatory picture has shifted.

Research log: what we checked

Where numbers appear below, they come from those sources. Claims we could not source are left out.

The trial design

FLOW (Evaluate Renal Function with Semaglutide Once Weekly) was a phase 3, randomized, double-blind, placebo-controlled trial. It enrolled 3,533 adults with type 2 diabetes and established chronic kidney disease (CKD) across 387 sites in 28 countries. Participants were randomized to once-weekly subcutaneous semaglutide, titrated from 0.25 mg up to a 1.0 mg maintenance dose, or to matching placebo, on top of standard care. Mean follow-up was about 3.4 years.

The primary outcome was a composite of major kidney disease events: onset of kidney failure (start of chronic kidney replacement therapy or a sustained eGFR below 15), a persistent reduction of at least 50% in eGFR, or death from kidney-related or cardiovascular causes. In other words, this was not a surrogate endpoint like a lab value trending in the right direction. It measured events patients and clinicians actually care about.

The headline result

The primary composite outcome occurred in 331 participants on semaglutide versus 410 on placebo — a 24% relative risk reduction (hazard ratio 0.76; 95% CI 0.66 to 0.88; p = 0.0003). The FDA later described this as roughly a 4.9% absolute risk reduction at three years.

Secondary findings pointed the same direction. Semaglutide was associated with a slower annual decline in kidney function, an 18% lower risk of major cardiovascular events, and a 20% reduction in all-cause mortality versus placebo. Supporting metabolic effects — reductions in urine albumin-to-creatinine ratio, body weight, HbA1c, and systolic blood pressure — were also reported, consistent with the drug's known profile.

Stopped early for efficacy

FLOW did not run to its originally planned conclusion. In October 2023, an independent Data Safety Monitoring Board reviewed a prespecified interim analysis after roughly 570 events had accrued and found that the predetermined efficacy stopping criteria were met. The trial was halted early.

Early stopping for efficacy is worth understanding rather than just cheering. When a trial ends ahead of schedule because a treatment is clearly working, that is a strong signal — but it can also modestly inflate effect-size estimates, and it means less long-term safety and durability data than a full run would have produced. FLOW's case is reassuring on this front: by the time follow-up wrapped, about 741 events had accumulated, close to the 854 originally planned, so the estimate rested on a substantial event count rather than a thin interim snapshot.

From trial to label

Regulators moved relatively quickly. On January 28, 2025, the FDA approved a new indication for Ozempic (semaglutide 1 mg): to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease. At approval it was described as the only GLP-1 receptor agonist carrying this kidney-and-cardiovascular indication. European regulators expanded the label along similar lines.

Two boundaries matter for reading that indication accurately. First, it applies to people who have both type 2 diabetes and CKD — FLOW did not test, and the approval does not cover, non-diabetic kidney disease. Second, the studied and approved dose here is the 1 mg Ozempic formulation, not the higher-dose weight-management product. Extrapolating beyond the enrolled population is exactly the kind of leap the evidence does not license.

Why this broadened GLP-1 beyond weight and glucose

For years, GLP-1 receptor agonists were framed by their two obvious jobs: lowering blood sugar and reducing body weight. FLOW reframed the class. It provided randomized, hard-endpoint evidence that semaglutide can slow the progression of kidney disease and reduce cardiovascular and overall mortality in a population where those outcomes are common and devastating.

That matters conceptually because it suggests the benefit is not merely downstream of weight or glucose. It positions semaglutide alongside other agents — such as SGLT2 inhibitors — that have earned organ-protective indications on their own outcome data, and it reinforces a broader shift in how metabolic drugs are evaluated: less by the numbers they move on a lab report, more by the events they prevent over years. FLOW is a large part of why "GLP-1" is no longer shorthand for "weight drug."

For the underlying molecule details and current regulatory scope, see the semaglutide page and FDA status.

PepStash is a research log and reference tool. This article is educational and is not medical advice — it does not diagnose, treat, or recommend any protocol. Regulatory status and trial data change; always verify against primary sources and consult a licensed physician before making any decisions about your health.